论文部分内容阅读
目的:探究临床治疗胃癌患者的过程中,应用替吉奥、奥沙利铂与热疗联合治疗的临床效果及其安全性,为临床肿瘤治疗奠定基础。方法:自我院2015年6月-2017年1月期间收治的85例胃癌患者,对比患者应用不同治疗措施的治疗效果及安全性。结果:予以不同治疗方案后,采用替吉奥、奥沙利铂与热疗联合治疗的试验组患者的临床有效率(86.67%,39/45)、无进展及中位生存时间均显著优于对照组,差异显著(P<0.05)。但两组间的不良反应(骨髓抑制、消化道反应、肝肾损伤等)发生率差异不显著(P>0.05)。结论:临床治疗胃癌患者的过程中,应用替吉奥、奥沙利铂与热疗联合治疗有利于治疗效果的提升,延长生存期,且安全可靠,应广泛推广。
OBJECTIVE: To explore the clinical effect and safety of combined treatment of tegaserod, oxaliplatin and hyperthermia in the clinical treatment of patients with gastric cancer, and lay the foundation for clinical oncology treatment. Methods: Eighty-five patients with gastric cancer who were admitted to our hospital from June 2015 to January 2017 were compared with the therapeutic effect and safety of different treatment measures. Results: The clinical efficacy (86.67%, 39/45), progression-free survival and median survival time of patients in the trial group treated with tegaserod and oxaliplatin combined with hyperthermia were significantly better than those of the control group Control group, the difference was significant (P <0.05). However, there was no significant difference in adverse reactions (such as bone marrow suppression, gastrointestinal reaction, liver and kidney injury) between the two groups (P> 0.05). Conclusion: In the clinical treatment of patients with gastric cancer, the application of the combination therapy of teglitazone and oxaliplatin with hyperthermia can promote the treatment effect, prolong survival, be safe and reliable, and should be widely popularized.